Thalidomide in Refractory Crohn's Disease: Risk-Benefit Ratio

$Thalidomide in Refractory Crohn's Disease: Risk-Benefit Ratio$

Journal article

Peer reviewed

Wael El-Matary and Wael El-Rifai

Clinical gastroenterology and hepatology, Vol.15(1), pp.148-148

2017-01-01

PMID: 27552856

Abstract

Gastroenterology & Hepatology

Life Sciences & Biomedicine

Science & Technology

1 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics: 1 Clinical & Life Sciences; 1.120 Inflammatory Bowel Diseases & Infections; 1.120.139 Ulcerative Colitis
Web Of Science research areas: Gastroenterology & Hepatology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Thalidomide in Refractory Crohn's Disease: Risk-Benefit Ratio
Creators: Wael El-Matary - University of Manitoba
Wael El-Rifai - UMMG Department of Surgery
Publication Details: Clinical gastroenterology and hepatology, Vol.15(1), pp.148-148
Publisher: Elsevier
Number of pages: 1
Grant note: Janssen Inc.; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc
Academic Unit: Miller School of Medicine; UMMG Department of Surgery; UMMG Dept of Surgery - Div of Surgical Oncology
Language: English
Resource Type: Journal article
PMID: 27552856
Record Identifier: 991031723371602976